International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention:...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Practice

Background:

• Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is standard after percutaneous coronary interventions.
• DAPT increases bleeding risk, necessitating individualized treatment strategies.
• Balancing bleeding and ischemic risks in patients is challenging.

Purpose of the Study:

• To provide expert recommendations on using platelet function and genetic testing to personalize P2Y12 inhibitor selection.
• To address the gap in current guidelines regarding the clinical implementation of these tests.

Main Methods:

• Review of current evidence on pharmacodynamic profiles of oral P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor).
• Analysis of data on high residual platelet reactivity and low platelet reactivity.
• Consensus development by a panel of international experts.

Main Results:

• Up to one-third of clopidogrel users show high residual platelet reactivity, increasing thrombotic risk.
• Prasugrel and ticagrelor are associated with low platelet reactivity and increased bleeding risk in some patients.
• Platelet function and genetic testing can guide P2Y12 inhibitor selection, but trial results are nonuniform.

Conclusions:

• Expert consensus provides guidance on tailoring antiplatelet therapy based on individual patient risk.
• Platelet testing may optimize P2Y12 inhibitor choice to improve outcomes after percutaneous coronary intervention.
• Further research and guideline updates are needed for widespread implementation.